MedPath

TYSABRI

TYSABRI

Approved
DIN Number

02286386

Drug Class

Human

Market Date

Nov 21, 2006

Company
HC

Biogen Canada Inc

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02286386
AIG Number0151674001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Schedule D ,  Prescription
A
ATC Code
L04AG03 NATALIZUMAB
Product Specifications
Dosage FormSolution
Route of AdministrationIntravenous
AHFS Classification92:20.00
Health Canada Classification

ACTIVE INGREDIENTS (1)

NATALIZUMABActive
Strength: 300 MG / 15 ML
Monograph: NATALIZUMAB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.